Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Victoza Settlement Sets Up Face-Off With Teva And Viatris

Novo Nordisk: Sandoz Able To Launch Liraglutide In June 2024

Executive Summary

Novo Nordisk’s cornerstone type 2 diabetes treatment Victoza is set to come under siege from the three largest generics manufacturers beginning in June 2024, after Sandoz became the last of the trio to sign a licensing agreement with the Danish originator that resolves patent-litigation proceedings.

You may also be interested in...



Invega Trinza, Pentasa, and Abilify LAI Top Viatris’ First Complex Ambitions

Viatris spent a good chunk of its recent investor day updating on its complex generics ambitions, especially considering it is set to be missing biosimilars from its armory in the back half of 2022. A proposed move for the first US generic Symbicort was suggested by management.

US FDA Approval Of Novo Nordisk's Victoza For Young T2D Patients A Treatment Milestone

The new indication means Victoza is the first non-insulin drug approved to treat type 2 diabetes in young patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.

Coherus Will Not Alert Filing Of Pegfilgrastim On-Body

Going toe-to-toe with Amgen on its Neulasta Onpro on-body injector device is a key strategic goal for Coherus BioSciences, although news will be kept concealed until the company’s proposed biosimilar is approved or launched.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel